Literature DB >> 15800957

Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data.

Marsha A Raebel1, Jennifer L Ellis, Susan E Andrade.   

Abstract

OBJECTIVE: Our aim was to evaluate the 270-day gestational age and delivery date assumptions used in an administrative dataset study assessing prenatal drug exposure compared to information contained in a birth registry. STUDY DESIGN AND
SETTING: Kaiser Permanente Colorado (KPCO), a member of the Health Maintenance Organization (HMO) Research Network Center for Education and Research in Therapeutics (CERTs), previously participated in a CERTs study that used claims data to assess prenatal drug exposure. In the current study, gestational age and deliveries information from the CERTs study dataset, the Prescribing Safely during Pregnancy Dataset (PSDPD), was compared to information in the KPCO Birth Registry. Sensitivity and positive predictive value (PPV) of the claims data for deliveries were assessed. The effect of gestational age and delivery date assumptions on classification of prenatal drug exposure was evaluated.
RESULTS: The mean gestational age in the Birth Registry was 273 (median = 275) days. Sensitivity of claims data at identifying deliveries was 97.6%, PPV was 98.2%. Of deliveries identified in only one dataset, 45% were related to the gestational age assumption and 36% were due to claims data issues. The effect on estimates of prevalence of prescribing during pregnancy was an absolute change of 1% or less for all drug exposure categories. For Category X, drug exposures during the first trimester, the relative change in prescribing prevalence was 13.7% (p = 0.014).
CONCLUSION: Administrative databases can be useful for assessing prenatal drug exposure, but gestational age assumptions can result in a small proportion of misclassification. Copyright (c) 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2005        PMID: 15800957     DOI: 10.1002/pds.1100

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  19 in total

1.  Quantifying clinical data quality using relative gold standards.

Authors:  Michael G Kahn; Brian B Eliason; Janet Bathurst
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

2.  Algorithms to estimate the beginning of pregnancy in administrative databases.

Authors:  Andrea V Margulis; Soko Setoguchi; Murray A Mittleman; Robert J Glynn; Colin R Dormuth; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-05-02       Impact factor: 2.890

3.  Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy.

Authors:  Robert L Davis; David Eastman; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Sascha Dublin; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-15       Impact factor: 2.890

4.  The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007.

Authors:  Lyndsay A Avalos; Hong Chen; Chunmei Yang; Susan E Andrade; William O Cooper; Craig T Cheetham; Robert L Davis; Sascha Dublin; Tarek A Hammad; Sigal Kaplan; Pamala A Pawloski; Marsha A Raebel; Pamela E Scott; David H Smith; Sengwee Toh; De-Kun Li
Journal:  Matern Child Health J       Date:  2014-01

5.  Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study.

Authors:  William V Bobo; Robert L Davis; Sengwee Toh; De-Kun Li; Susan E Andrade; T Craig Cheetham; Pamala Pawloski; Sascha Dublin; Simone Pinheiro; Tarek Hammad; Pamela E Scott; Richard A Epstein; Patrick G Arbogast; James A Morrow; Judith A Dudley; Jean M Lawrence; Lyndsay A Avalos; William O Cooper
Journal:  Paediatr Perinat Epidemiol       Date:  2012-11       Impact factor: 3.980

6.  Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes.

Authors:  Karin E Johnson; Sarah J Beaton; Susan E Andrade; T Craig Cheetham; Pamela E Scott; Tarek A Hammad; Inna Dashevsky; William O Cooper; Robert L Davis; Pamala A Pawloski; Marsha A Raebel; David H Smith; Sengwee Toh; De-Kun Li; Katherine Haffenreffer; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-04-18       Impact factor: 2.890

7.  Validation of an algorithm to estimate gestational age in electronic health plan databases.

Authors:  Qian Li; Susan E Andrade; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; Inna Dashevsky; Katherine Haffenreffer; Karin E Johnson; Sengwee Toh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-21       Impact factor: 2.890

8.  Randomized trial to improve prescribing safety during pregnancy.

Authors:  Marsha A Raebel; Nikki M Carroll; Julia A Kelleher; Elizabeth A Chester; Sally Berga; David J Magid
Journal:  J Am Med Inform Assoc       Date:  2007-04-25       Impact factor: 4.497

9.  Medication exposure in pregnancy risk evaluation program: the prevalence of asthma medication use during pregnancy.

Authors:  Craig Hansen; Peter Joski; Heather Freiman; Susan Andrade; Sengwee Toh; Sascha Dublin; Craig Cheetham; William Cooper; Pamala Pawloski; De-Kun Li; Sarah Beaton; Sigal Kaplan; Pamela Scott; Tarek Hammad; Robert Davis
Journal:  Matern Child Health J       Date:  2013-11

10.  Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.

Authors:  Susan E Andrade; Sengwee Toh; Monika Houstoun; Katrina Mott; Marilyn Pitts; Caren Kieswetter; Carrie Ceresa; Katherine Haffenreffer; Marsha E Reichman
Journal:  Matern Child Health J       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.